Last reviewed · How we verify

Imcivree — Competitive Intelligence Brief

Imcivree (SETMELANOTIDE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Melanocortin 4 Receptor Agonist [EPC]. Area: Metabolic.

marketed Melanocortin 4 Receptor Agonist [EPC] Melanocortin receptor 4 Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Imcivree (SETMELANOTIDE) — Rhythm. Imcivree works by activating the melanocortin 4 receptor, a protein that helps regulate appetite and metabolism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Imcivree TARGET SETMELANOTIDE Rhythm marketed Melanocortin 4 Receptor Agonist [EPC] Melanocortin receptor 4 2020-01-01
Cortrosyn tetracosactide Amphastar Pharms Inc marketed Adrenocorticotropic Hormone [EPC] Melanocortin receptor 4 1970-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Melanocortin 4 Receptor Agonist [EPC] class)

  1. Rhythm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imcivree — Competitive Intelligence Brief. https://druglandscape.com/ci/setmelanotide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: